Abstract 3913
Background
Hand-foot syndrome (HFS) is an adverse effect which triggered by chemotherapy, Capecitabine has the highest reported HFS incidence at about 50% to 60%. LC09 is composed of Chinese herbs and is used to soak hands and feet. Former clinical study and animal experiment have shown that Chinese herbal compound LC09 can alleviate numb, pain and inflammation. This study is aimed to evaluate its validity via strictly randomized, double-blind, placebo-controlled trial.
Methods
156 patients which is diagnosed as HFS randomly assigned 1:1 to treatment group (n = 78) and control group (n = 78) in 4 centers. Intervention of LC09 or placebo is lasting for 6 weeks and evaluated every week by NCI degree, NRS pain scores. Assess quality of life using DLQI (dermatology life quality index) scale and IADL (instrumental activity of daily living) scale at the beginning one week later and the end.
Results
NCI degree and NRS pain scores between two groups are significant difference (p < 0.001). HFS effective rate (70.4%) and pain alleviated rate (81.9%) of treatment group are significantly higher than control group (p < 0.001). There is no intense evidence identify the effect for quality of life with LC09 after assessing by DLQI scale and IADL scale. Chemical completion rate between two groups is significantly different, P = 0.0021.
Conclusions
Chinese herbal compound LC09 can decrease NCI degree and alleviate pain significantly. Besides, it can also increase chemical completion rate. But effect for quality of life still needs to search with more specific scale.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Ministry of Science and Technology of the People’s Republic of China (2015BAI04B07).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5141 - Mutational profiling of tumor tissue and sequential plasma illustrates emergent clones during treatment in late stage small cell lung cancer (SCLC)
Presenter: Stephanie Yaung
Session: Poster Display session 1
Resources:
Abstract
5189 - Association between serum HGF levels and neutrophil counts in small cell lung cancer and their impact on survival
Presenter: Laura Moliner
Session: Poster Display session 1
Resources:
Abstract
3539 - Prognostic role of RLF/MYCL1 and circPVT1 in SCLC.
Presenter: Clelia Tiziana Storlazzi
Session: Poster Display session 1
Resources:
Abstract
3438 - High-biologically effective dose radiotherapy improve the survival of small cell lung cancer patients with brain metastases: a propensity-matching analysis
Presenter: Qingyang Zhuang
Session: Poster Display session 1
Resources:
Abstract
3232 - Phase 1 open-label study evaluating the safety, pharmacokinetics, and preliminary efficacy of ABBV-181 and rovalpituzumab tesirine (ROVA-T) in patients with small cell lung cancer
Presenter: Emiliano Calvo
Session: Poster Display session 1
Resources:
Abstract
3633 - Activity of the novel Aurora kinase B inhibitor AZD2811 in biomarker-defined models of small cell lung cancer
Presenter: Carminia Maria Della Corte
Session: Poster Display session 1
Resources:
Abstract
3745 - Multi-level proteomics identifies FABP5 as a primary chemoresistance mediator in extensive-stage small cell lung cancer
Presenter: Yamei Chen
Session: Poster Display session 1
Resources:
Abstract
5049 - CLEPSIDRA trial: a pilot, biomarker-guided study to assess safety, tolerability, dose finding and efficacy of iadademstat in combination with platinum-etoposide in patients with relapsed, extensive-stage small cell lung cancer
Presenter: Alejandro Navarro Mendivil
Session: Poster Display session 1
Resources:
Abstract
5997 - Phased Avelumab combined with chemotherapy as first-line treatment for patients with advanced small-cell lung cancer (SCLC): The PAVE study, a Hellenic Cooperative Oncology Group Study
Presenter: Helena Linardou
Session: Poster Display session 1
Resources:
Abstract
4502 - Tobacco use in lung cáncer (LC) patients (p) in Spain
Presenter: Enric Carcereny Costa
Session: Poster Display session 1
Resources:
Abstract